Compare Medpace Holdings Inc (MEDP) vs Sibanye Stillwater Ltd (SBSW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Sibanye Stillwater Ltd — how do they compare? Medpace Holdings Inc trades at $533.71 (market cap $15.08B), while Sibanye Stillwater Ltd trades at $8.57 (market cap $5.66B). The key difference: Medpace Holdings Inc is far larger — about 2.7× Sibanye Stillwater Ltd's market cap, and Sibanye Stillwater Ltd pays a 3.89% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | SBSW | |
|---|---|---|
Market Cap | $15.08B | $5.66B |
Sector | Technology | Basic Materials |
52-Week High | $620.59 | $21.12 |
52-Week Low | $308.88 | $7.27 |
Enterprise Value | $14.55B | $7.28B |
Dividend Yield | — | 3.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
Sibanye Stillwater (SBSW) trades at $8.02, up 0.25% on the day, with technical indicators showing a bearish trend. The company reported a net loss of $7.30 billion in 2024, though revenue remained stable at $112.13 billion. Recent news highlights management's focus on debt reduction and operational improvements, with Seeking Alpha noting a 5x YoY EBITDA surge driven by strong PGM and gold prices as of July 3, 2026.
The stock presents a high-risk opportunity with a consensus price target of $14.25, implying significant upside, but faces headwinds from negative profitability metrics and volatile commodity prices. Investors should weigh the potential turnaround against ongoing operational challenges and macroeconomic risks in the mining sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →
